Comparison of the hemostatic efficacy of pathogen-reduced platelets vs Untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: A randomized clinical trial

JAMA Oncology

Volumn 4, Issue 4, 2018, Pages 468-475

  Garban, Frédéric ^a,b,c   Guyard, Audrey ^b,d   Labussière, Helene ^a,e   Bulabois, Claude Eric ^b   Marchand, Tony ^f   Mounier, Christiane ^g,s   Caillot, Denis ^h   Bay, Jacques Olivier ⁱ   Coiteux, Valérie ^j   Schmidt Tanguy, Aline ^k   Le Niger, Catherine ^l   Robin, Christine ^m   Ladaique, Patrick ⁿ   Lapusan, Simona ^o   Deconinck, Eric ^p   Rolland, Carole ^a   Foote, Alison M ^b   Anne, François ^c   Chantal, Jacquot ^c   René, Tardivel ^c   Pierre, Tiberghien ^c,q   Jean Luc, Bosson ^b,d   Bierling, Philippe ⁱ   Carre, Martin ^b   Cordonnier, Catherine ^m   Gimeno, Linda ^c   Guillerm, Gaelle ^l   Hunault, Mathilde ^k   Lamy, Thierry ^f   Legrand, Dominique ^c   Michallet, Mauricette ^e   Tavernier, Emmanuelle ^g,s   Verkhoff, Anne ^r   Agua, Ibrahim Yakoub ^j   Doroszewski, Fanny ^b   Gavard, Marie Laure ^b   more..

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d INSERM   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g Lucien Neuwirth Cancer Institute   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l BREST UNIVERSITY HOSPITAL   (France)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p UNIVERSITY HOSPITAL OF BESANÇON   (France)

^q UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^r HÔPITAL SAINT ANTOINE   (France)

^s Institut de Cancérologie   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; DRUG ADDITIVE; THROMBOCYTE CONCENTRATE; HEMOSTATIC AGENT;

ADULT; ARTICLE; BLEEDING; BONE MARROW APLASIA; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FRANCE; HEMATOLOGIC MALIGNANCY; HEMOSTASIS; HUMAN; HUMAN CELL; INFECTIOUS AGENT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOGEN REDUCED PLATELET; PLASMA; RANDOMIZED CONTROLLED TRIAL; TERTIARY CARE CENTER; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRAVIOLET A RADIATION; UNIVERSITY HOSPITAL; WORLD HEALTH ORGANIZATION; AGED; BLOOD SAFETY; CLINICAL TRIAL; CYTOLOGY; DISEASE TRANSMISSION; DISINFECTION; EQUIVALENCE TRIAL (TOPIC); HEMATOLOGIC DISEASE; PHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES;

ADULT; AGED; BLOOD PLATELETS; BLOOD SAFETY; DISEASE TRANSMISSION, INFECTIOUS; DISINFECTION; EQUIVALENCE TRIALS AS TOPIC; FEMALE; FRANCE; HEMATOLOGIC DISEASES; HEMOSTASIS; HEMOSTATICS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 85047476557     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.5123     Document Type: Article

References (39)

1. Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007;370(9585):427-438.
2. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion. 2010;50(10): 2080-2099.
3. Brecher ME, Hay SN. Bacterial contamination of blood components. Clin Microbiol Rev. 2005;18(1): 195-204.
4. Lafeuillade B, Eb F, Ounnoughene N, et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion. 2015;55 (3):636-646.
5. Pietersz RNI, Reesink HW, Panzer S, et al. Bacterial contamination in platelet concentrates. Vox Sang. 2014;106(3):256-283.
6. Prowse CV. Component pathogen inactivation. Vox Sang. 2013;104(3):183-199.
7. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System™. Transfus Med Hemother. 2011;38(1):19-31.
8. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood. 2014;123(5): 796-797.
9. Schmidt M, Hourfar MK, SireisW, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion. 2015;55(9):2104-2112.
10. Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014;28(6):235-241.
11. Osman A, Hitzler WE, Meyer CU, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets. 2015;26(2):154-163.
12. Kerkhoffs JL, van Putten WL, Novotny VM, et al; Dutch-Belgian HOVON Cooperative Group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209-217.
13. Rebulla P, Vaglio S, Beccaria F, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion. 2017;57(5):1171-1183.
14. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2013;3(3): CD009072.
15. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017;7: CD009072.
16. World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
17. Transfusion of platelets in hematologyoncology medicine. http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-11/fiche-de-synthese-transfusion-de-plaquettes-en-medecine-hematologie-oncologie.pdf. Accessed September 30, 2017.
18. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362 (7):600-613.
19. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771-1780.
20. Wandt H, Schaefer-Eckart K, Wendelin K, et al; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies. Lancet. 2012;380(9850):1309-1316.
21. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med (Chic). 1916;17:863-871.
22. Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26(2):192-196.
23. Dinno A. tostpr: One- and two-sample z tests of proportion-equivalence. Stata software package 2016. https://www.alexisdinno.com/stata/tostpr.txt. Accessed March 29, 2017.
24. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. Blood. 2004;104(5):1534-1541.
25. Ypma PF, van der Meer PF, Heddle NM, et al; PREPAReS Study Group. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products. BMJ Open. 2016;6(1):e010156.
26. Engels JM, Diehr P. Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003;56(10):968-976.
27. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42(5):556-566.
28. Ringwald J, Zimmermann R, Eckstein R. The new generation of platelet additive solution for storage at 22 degrees C. Transfus Med Rev. 2006; 20(2):158-164.
29. Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood. 2006;108(9):3210-3215.
30. Murphy S. Radiolabeling of PLTs to assess viability. Transfusion. 2004;44(1):131-133.
31. Snyder E, McCullough J, Slichter SJ, et al; SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation. Transfusion. 2005;45(12):1864-1875.
32. van Rhenen D, Gulliksson H, Cazenave JP, et al; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment. Blood. 2003;101 (6):2426-2433.
33. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393-401.
34. van Hout FMA, Bontekoe IJ, de Laleijne LAE, et al. Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography. Vox Sang. 2017;112(6):549-556.
35. Daurat A, Roger C, Gris J, et al. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors. Transfusion. 2016;56(6): 1295-1303.
36. Corash L, Lin JS, Sherman CD, Eiden J. Determination of acute lung injury after repeated platelet transfusions. Blood. 2011;117(3):1014-1020.
37. Hess JR, Pagano MB, Barbeau JD, Johannson PI. Will pathogen reduction of blood components harm more people than it helps in developed countries? Transfusion. 2016;56(5):1236-1241.
38. Arbaeen AF, Schubert P, Serrano K, Carter CJ, Culibrk B, Devine DV. Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols. Transfusion. 2017;57(5):1208-1217.
39. NussbaumerW, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang. 2017;112(3):249-256.